The transcription factor p53 (also known as TP53) guards against tumour and virus replication and is inactivated in almost all cancers. p53-activated transcription of target genes is thought to be synonymous with the stabilization of p53 in response to oncogenes and DNA damage. During adenovirus replication, the degradation of p53 by E1B-55k is considered essential for p53 inactivation, and is the basis for p53-selective viral cancer therapies. Here we reveal a dominant epigenetic mechanism that silences p53-activated transcription, irrespective of p53 phosphorylation and stabilization. We show that another adenoviral protein, E4-ORF3, inactivates p53 independently of E1B-55k by forming a nuclear structure that induces de novo H3K9me3 heterochromatin formation at p53 target promoters, preventing p53-DNA binding. This suppressive nuclear web is highly selective in silencing p53 promoters and operates in the backdrop of global transcriptional changes that drive oncogenic replication. These findings are important for understanding how high levels of wild-type p53 might also be inactivated in cancer as well as the mechanisms that induce aberrant epigenetic silencing of tumour-suppressor loci. Our study changes the longstanding definition of how p53 is inactivated in adenovirus infection and provides key insights that could enable the development of true p53-selective oncolytic viral therapies.
The transcription factor p53 (also known as TP53) guards against tumour and virus replication and is inactivated in almost all cancers. p53-activated transcription of target genes is thought to be synonymous with the stabilization of p53 in response to oncogenes and DNA damage. During adenovirus replication, the degradation of p53 by E1B-55k is considered essential for p53 inactivation, and is the basis for p53-selective viral cancer therapies. Here we reveal a dominant epigenetic mechanism that silences p53-activated transcription, irrespective of p53 phosphorylation and stabilization. We show that another adenoviral protein, E4-ORF3, inactivates p53 independently of E1B-55k by forming a nuclear structure that induces de novo H3K9me3 heterochromatin formation at p53 target promoters, preventing p53-DNA binding. This suppressive nuclear web is highly selective in silencing p53 promoters and operates in the backdrop of global transcriptional changes that drive oncogenic replication. These findings are important for understanding how high levels of wild-type p53 might also be inactivated in cancer as well as the mechanisms that induce aberrant epigenetic silencing of tumour-suppressor loci. Our study changes the longstanding definition of how p53 is inactivated in adenovirus infection and provides key insights that could enable the development of true p53-selective oncolytic viral therapies.
Tumour mutations and DNA virus proteins converge in inactivating p53 (ref. 1), which was initially discovered as a cellular target of SV40 Large T 2,3 . However, despite 30 years of research, the critical factors that determine p53-activated transcription are still not fully understood 4, 5 . p53 is expressed constitutively in normal cells where its activity is limited by p53 protein degradation 6 . p53 activation is triggered in response to oncogenes and DNA damage, which stabilize p53 (refs 7-9) . This has led to the general belief that the induction of p53 levels and phosphorylation 10 is synonymous with p53-activated transcription. As such, the induction of p53 levels is a standard readout for p53 activation and rationale for several cancer therapies, including irradiation and genotoxic drugs 11 , MDM2 antagonists 12 , and the E1B-55k-deleted oncolytic adenoviral therapy, ONYX-015 (ref. 13) .
The adenoviral protein, E1B-55k, binds to the p53 transactivation domain and is sufficient to inactivate p53 in cellular transformation 7, 14 . In infection, E1B-55k forms a complex with another adenoviral protein, E4-ORF6, which recruits a cellular ubiquitin ligase that targets p53 for degradation 15, 16 . The degradation of p53 by E1B-55k is thought to be the critical event that inactivates p53 for virus replication 17 . An E1B-55k-deleted virus 18 , dl1520/ONYX-015, induces high p53 levels, which was expected to limit viral replication in normal cells but not p53 mutant tumour cells 13 . On this basis, ONYX-015 (ref. 13 ) was tested in patients as a p53 tumour-selective oncolytic viral therapy 19, 20 and is now approved in several countries (known as Oncorine). However, the loss of E1B-55k functions in viral RNA export, rather than p53 inactivation, is the major determinant of DE1B-55k tumour selectivity 21, 22 . Contrary to expectations, although p53 accumulates to high levels in the nucleus of DE1B-55k (D55k)infected human primary small airway epithelial cells (SAECs), the physiological target cells for adenovirus infection, p53 transcriptional targets, such as p21 (also known as CDKN1), MDM2, CCNG, 14-3-3s (also known as SFN), PERP, PIG3 (also known as TP53I3) and GADD45, are not induced ( Fig. 1a and ref. 21 ). The failure of p53 stabilization to activate transcriptional targets is not a tissue-specific effect and occurs in multiple primary cell types and tumour cell lines ( Supplementary Figs 1-3 ), including U2OS tumour cells where p53 targets are suppressed to a similar extent as that in celllines with p53 mutations. This reveals a fundamental gap in our understanding of not only adenovirus biology but also p53 activation.
p53 stabilization without activity Cellular and viral oncogenes, such as Ras and adenovirus E1A, trigger p53 activation by inducing the expression of ARF 9 , which inhibits MDM2-mediated p53 degradation. ARF is lost in 58% of cancers 9 , which had previously been invoked as the critical factor that prevents p53 activation in DE1B-55k-infected tumour cells 23 . Using a U2OS stable cell-line (p53 wild-type, ARF negative) in which ARF expression is induced by isopropyl-b-D-thiogalactopyranoside (IPTG), we show that ARF stabilizes p53 and activates p21 transcription in mock infection. Nevertheless, although ARF expression increases basal p53 activity, the induction of p21 is repressed in both wild-type-and DE1B-55k-infected cells ( Fig. 1b and Supplementary Fig. 4 ). Furthermore, endogenous ARF induction also fails to activate p53 targets in DE1B-55k-infected SAECs (Fig. 1a ). Thus, p53 is inactivated, irrespective of E1B-55k and ARF expression in adenovirusinfected cells.
DNA damage signals also have a critical role in activating p53, triggering p53 phosphorylation and protein stabilization 8, 24 . In clinical trials, DE1B-55k (ONYX-015), was used in combination with genotoxic chemotherapies, such as 5-fluorouracil 19, 20 . We reasoned that the induction of p53 levels alone may not be sufficient to activate p53 in infected cells, and that DNA damage is also required. However, 5-fluorouracil fails to activate p53 in DE1B-55k-infected U2OS cells ( Supplementary Fig. 5 ). The DNA damage checkpoint is deregulated in many tumour cells. Therefore, we also analysed DE1B-55k-infected SAECs and show that p53 transcriptional targets cannot be activated by c irradiation ( Fig. 1c and Supplementary Fig. 6 ), ultraviolet irradiation ( Supplementary Fig. 7 ) or doxorubicin (dox, Fig. 1e ).
The activation of p53 in response to DNA damage is mediated via kinases, such as ATM, ATR, DNA-PKcs (also known as PRKDC), CHK1 and CHK2, which phosphorylate p53 (ref. 8) at key residues, stabilizing p53 and potentiating p53-DNA binding 24 . A possible explanation for the failure of DNA damage to activate high p53 levels in DE1B-55k-infected cells is that p53 phosphorylation is inhibited by viral infection. However, even without the introduction of exogenous genotoxic stress, p53 is already highly phosphorylated at multiple sites targeted by DNA damage kinases in DE1B-55k-infected SAECs (Fig. 1d ). Thus, although oncogenes and DNA damage trigger p53 stabilization and phosphorylation in DE1B-55k-infected cells, p53 fails to activate the transcription of downstream effectors.
We next examined if, in the absence of E1B-55k, MDM2 binds and inactivates p53 in adenovirus-infected cells. Nutlin is a small molecule antagonist that inhibits MDM2-p53 binding 12 . In contrast to mock, nutlin fails to stabilize p53 further or induce p21 in DE1B-55k-infected SAECs (Fig. 1e ). The histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), induces the expression of p21 independently of p53 stabilization or phosphorylation ( Fig. 1e ). However, in DE1B-55kinfected cells, TSA fails to induce p21. We conclude that p53 transcriptional targets are dominantly suppressed in adenovirus-infected cells, irrespective of E1B-55k, and cannot be activated in response to radiation, genotoxic drugs, ARF, MDM2 antagonists or HDAC inhibitors.
E4-ORF3 inactivates p53 independently of E1B-55k
Our data strongly indicate that there is a previously undiscovered adenoviral protein that inactivates p53 independently of p53 degradation. To test this, we screened for p53 activation in primary cells infected with adenoviruses that have compound mutations in E1B-55k and other early viral genes ( Supplementary Fig. 8 ). In addition to deleting E1B-55k, the loss of either E1A-13s or E4-ORF3 is required to activate p53 in infected cells ( Fig. 2a ). This is surprising, especially because E1A is a potent oncogene that triggers p53 activation in cellular transformation 7, 14 . In adenovirus infection, the E1A-13s splice form is required for the transactivation of other viral genes 17 , including E4-ORF3 ( Fig. 2a ). Consistent with this, we show that, in contrast to GFP (green fluorescent protein), the ectopic expression of E4-ORF3 rescues p53 inactivation in both DE1B-55k/DE4-ORF3and DE1B-55k/DE1A-13sinfected cells (Fig. 2b) . The slight reduction of p21 by Ad-GFP in DE1B-55k/DE4-ORF3 co-infection is due to the partial activation of E4-ORF3 transcription (in trans) by E1A-13s, which does not occur in DE1B-55k/ DE1A-13s co-infection ( Supplementary Fig. 9 ). Hence, E1A-13s induces the expression of E4-ORF3, which then inactivates p53 via an E1B-55k-independent mechanism. Moreover, the expression of E4-ORF3 alone is also sufficient to inhibit p53 activation (Supplementary Fig. 10 ). These data reveal E4-ORF3 as a novel adenoviral protein that inactivates the p53 tumour-suppressor pathway.
The proposed p53 tumour selectivity of the DE1B-55k oncolytic therapy, ONYX-015, is based on p53 stabilization being the sole critical event that determines p53-activated transcription. Although there is Mock  0  24 36 48  24 36 48 24 36 48  24 36 48  24 36 ARTICLES some basal p53 activity in DE1B-55k-infected cells compared to wildtype virus, the additional deletion of E4-ORF3 is necessary for p53 to activate downstream effectors over the course of infection ( Fig. 2c, d) . In contrast to p53 transcriptional targets, the mRNA levels of p53 and the housekeeping gene, GUSB, are not impacted by E4-ORF3 ( Supplementary Fig. 11 ). p53 stabilization is required to activate p53 transcriptional targets, and does not occur in DE4-ORF3 infection where p53 is degraded by E1B-55k/E4-ORF6. Furthermore, using a p53-inducible stable cell-line (H1299-D1, Supplementary Fig. 12 ), we show that the induction of p21 and MDM2 in DE1B-55k/DE4-ORF3 infection is p53-dependent. Thus, the deletion of both E1B-55k and E4-ORF3 is necessary to activate p53 in adenovirus infection. We conclude that E4-ORF3 has a critical and novel role in inactivating p53 independently of E1B-55k and p53 degradation.
E4-ORF3 prevents p53-DNA binding at chromatin DNA tumour virus proteins, such as E1B-55k, SV40 LT and HPV E6, inactivate p53 via direct high affinity protein-protein interactions 1 . However, contrary to this established paradigm, E4-ORF3 does not co-localize with p53 ( Supplementary Fig. 13 ) or co-immunoprecipitate with p53 (data not shown). This indicates that E4-ORF3 inactivates p53 via a non-canonical mechanism.
The induction of p53 levels and phosphorylation induces p53 conformational changes that drive sequence-specific DNA binding and the recruitment of transcription co-factors 25 . A p53-DNA binding domain that is competent to bind to DNA can be distinguished by immunoprecipitation with monoclonal antibody PAb1620 versus PAb240 (ref. 26) . p53 is immunoprecipitated selectively by PAb1620 in both DE1B-55kand DE1B-55k/DE4-ORF3-infected cells ( Supplementary Fig. 14) , demonstrating that the p53 DNAbinding domain is in a protein conformation that should be capable of binding to DNA 26 in both cases. To determine functionally if E4-ORF3 prevents p53-DNA binding, we transfected U2OS cells with a p53 luciferase plasmid (p53-luc), where p53 binding to consensus DNA sequences activates luciferase transcription 27 . A control pGL3luciferase reporter (non-p53 promoter) is activated to similar levels in all viral infections ( Supplementary Fig. 15 ). In wild-type-virusinfected cells, p53-activated transcription of luciferase is inhibited after 24 h ( Fig. 3a) , which is expected due to p53 degradation. In contrast, p53-luciferase is activated in both DE1B-55k and DE1B-55k/DE4-ORF3 infection (Fig. 3a) . The induction of luciferase requires p53-DNA binding, since a mutated p53 response element (p53-mutant) abolishes luciferase activity. These experiments demonstrate that E4-ORF3 does not compete with p53 for binding to consensus DNA target sequences or prevent p53 transcriptional activation of promoters in ectopic reporter plasmids.
The ability of E4-ORF3 to prevent p53-activated transcription of endogenous targets, but not ectopic p53-luciferase plasmids, is at first difficult to reconcile. Plasmid DNA is not subject to the same architectural and packing constraints as DNA in cellular chromatin. Therefore, we performed p53 chromatin immunoprecipitations (ChIPs) to determine if E4-ORF3 specifically prevents p53-DNA binding in the context of cellular chromatin. p53 binding to target sites in the p21 (59 and 39 site) and MDM2 promoters 25 is induced upon doxorubicin treatment and DE1B-55k/DE4-ORF3 infection, where it activates the transcription of p21 and MDM2 RNAs (Fig. 3b, c) . In contrast, although p53 is induced to similar levels, E4-ORF3 prevents p53-DNA binding to the p21 and MDM2 promoters in DE1B-55k-infected cells (Fig. 3b, c and Supplementary Fig.  16 ). Thus, E4-ORF3 inactivates p53 by preventing p53 binding to DNA target sites specifically in the context of cellular chromatin. 
Repressive histone methylation silences p53 targets
We reasoned that p53-DNA binding depends not only on the protein conformation of p53 but also the accessibility of target promoters in the cellular genome. We proposed that E4-ORF3 could inactivate p53 by inducing heterochromatin at endogenous target promoters, preventing the access of p53 to DNA. Heterochromatin compaction is specified by the loss of histone acetylation and induction of repressive histone methylation 28 . TSA fails to induce p21 in DE1B-55k-infected SAECs (Fig. 1e) , indicating that E4-ORF3 inactivates p53 targets via a mechanism that is dominant to the inhibition of histone deacetylation. In cancer, the aberrant epigenetic silencing of tumour-suppressor genes, such as p16 INK4a (also known as CDKN2A), is initiated by the methylation of histone H3 at lysine 9 (H3K9) 29 . p53 localization is indistinguishable in DE1B-55kand DE1B-55k/DE4-ORF3-infected cells (Fig. 3d ). However, in DE1B-55k-infected cells, where p53 is inactive, dense regions of H3K9me3 repressive heterochromatin are induced at the periphery of the nucleus ( Fig. 3d and Supplementary  Fig. 17 ). Of the four known methyltransferases that catalyse H3K9 trimethylation (H3K9me3), we show that SUV39H1 and SUV39H2 (which share 59% sequence identity and have redundant functions) 30, 31 , but not SETDB1 (ref. 32) or G9a (also known as EHMT2, ref. 33) , are specifically associated with the formation of de novo H3K9me3 heterochromatin domains in DE1B-55k-infected nuclei (Fig. 3e ). The formation of these domains requires E4-ORF3 and does not occur in either mock-or DE1B-55k/DE4-ORF3-infected cells ( Supplementary Figs 18-21) .
These data demonstrate that E4-ORF3 induces novel H3K9me3 heterochromatin, which could deny p53 access to endogenous target promoters. To test this, we performed p53 and H3K9me3 ChIPs. The induction of repressive heterochromatin by E4-ORF3 is not associated with a global upregulation of either total histone H3 or H3K9me3, which are at similar levels in all infections (Fig. 4a) . In DE1B-55k/DE4-ORF3-infected cells, p53 binding is induced at p21 and MDM2 promoter sites (consistent with Fig. 3c ), whereas H3K9me3 is at a similar level to an IgG-negative control ( Fig. 4a and Supplementary Fig. 22 ). In contrast, in DE1B-55k-infected cells, H3K9me3 is enriched at the p21 and MDM2 promoters where p53 binding is prevented. H3K9me3 is also induced at the 25 kb region of the p21 promoter and is not restricted to p53 binding sites ( Supplementary Fig. 22 ). Thus, in cells expressing E4-ORF3, there is an inverse correlation between p53 and H3K9me3 at p53-regulated promoters. The same conclusions were reached for additional p53 targets, including GADD45A, FAS, PUMA (also known as BBC3) and PIG3 ( Supplementary Figs 22-24) . In contrast, at non-p53-regulated promoters, such as ACTIN (also known as ACTA) and POLR2, H3K9me3 is not induced in DE1B-55k-infected cells relative to mock ( Supplementary Figs 22 and 24) . Basal H3K9me3 is decreased at these promoters in DE1B-55k/DE4-ORF3-infected cells, indicating that E4-ORF3 may also restrain global demethylase activity. We conclude that E4-ORF3 inactivates p53 by inducing de novo H3K9me3 heterochromatin silencing at p53 target promoters. With access denied, p53 is powerless to activate the transcription of downstream effectors.
The induction of heterochromatin formation is still relatively poorly understood. Thus, a major question is how is E4-ORF3 directly involved in inducing repressive H3K9me3 heterochromatin at p53 target promoters? E4-ORF3 does not co-localize with p53 and forms a distinctive web-like structure in the nucleus ( Supplementary  Fig. 13 ). We show that E4-ORF3 demarcates the formation of de novo H3K9me3 heterochromatin domains in DE1B-55k-infected cells. E4-ORF3 is, for the most part, adjacent to H3K9me3, indicating it acts as a novel platform that catalyses heterochromatin formation through transient or long-range interactions ( Supplementary Figs 25-27 ). Using high-resolution confocal microscopy, we show that E4-ORF3 forms a continuous scaffold that specifies de novo heterochromatin assembly as it weaves through the nucleus (Fig. 4b) . These data demonstrate a direct role for E4-ORF3 in orchestrating H3K9me3 heterochromatin silencing at p53 target promoters. Furthermore, they reveal an extraordinary nuclear scaffold that either builds on existing architectural features that organize cellular DNA or is a novel viral construction that targets heterochromatin assembly at p53 target promoters.
Selective silencing of the p53 transcription program
These data beg the question as to the specificity of E4-ORF3 in silencing p53 targets. To determine the global consequences on cellular transcription, we performed genome-wide expression analyses on infected SAECs ( Supplementary Figs 28 and 29 ). These studies demonstrate that E4-ORF3 is an exclusive player in the global transcriptional changes induced upon viral infection. There are 1,730 overlapping genes that are similarly up or downregulated by a log-fold change greater than two in both DE1B-55k and DE1B-55k/DE4-ORF3 versus mock, which reflect a common transcriptional program (Fig. 5a ). These global changes are associated with the cell cycle and E2F activation ( Supplementary Tables 1 and 2 ). This is consistent with E1Amediated inactivation of RB 34 and recruitment of p300 and PCAF (also known as EP300 and KAT2B, respectively) to induce active histone acetylation marks at the promoters of genes involved in cell growth, division and DNA synthesis 35, 36 . Thus, E4-ORF3-induced heterochromatin silencing, as well as the scaffold it forms throughout the nucleus, does not affect the global activation of cellular transcripts induced by viral infection.
To define the genes specifically targeted by E4-ORF3, we compared DE1B-55k/DE4-ORF3versus DE1B-55k-infected cells. E4-ORF3 prevents the transcriptional activation of 265 genes by a log-fold change of two or more in DE1B-55k-infected cells. To determine how many of these genes are likely to be regulated by p53, we used two criteria: the presence of consensus p53-DNA binding sites in their promoters and their induction upon treatment with the MDM2 antagonist, nutlin. A heat map of top transcripts differentially upregulated in response to DE1B-55k/DE4-ORF3 and nutlin includes well known p53 targets (MDM2, FAS, PIG3, TP53INP1, BTG2, LRDD) associated with growth inhibition and apoptosis, as well as novel targets (HRH1, RNASE7, JMJD1C) ( Fig. 5b and Supplementary Fig. 30 ). Of the 265 differentially upregulated genes, 73% are induced in response to nutlin and/or have predicted p53 binding sites ( Fig. 5c and Supplementary Tables 3, 4) . A pathway analysis of E4-ORF3-regulated transcripts indicates that, in addition to the p53 pathway, there is a significant over-representation of genes associated with immune modulation as well as tissue/vascular remodelling (Supplementary Table 5 ). These data indicate that E4-ORF3 may target p53 promoters as part of a general anti-viral transcriptional silencing program, which is consistent with the highly defective replication of DE1B-55k/DE4-ORF3 in primary cells ( Supplementary Fig. 31 ).
Discussion and perspective
The conclusions of our study challenge the general assumption that p53 induction and phosphorylation is tantamount to p53 activity, which is the premise for several cancer therapies [11] [12] [13] . Our data reveal a novel and dominant mechanism of p53 inactivation that acts through the targeted epigenetic silencing of p53 target promoters. We identify a viral protein, E4-ORF3, which seems to form a novel scaffold that weaves through the nucleus, directing SUV39H1/2 H3K9me3 heterochromatin assembly at p53 target promoters to silence p53-activated transcription in response to genotoxic and oncogenic stress (Fig. 5d ). Remarkably, this suppressive nuclear web selectively ensnares p53 and anti-viral genes while operating in the backdrop of global transcriptional changes that drive pathological cellular and viral replication.
There is a profound functional overlap between adenovirus early proteins and tumour mutations 37 . Thus, a major question is if E4-ORF3 reflects or exhorts an existing cellular mechanism and nuclear structure that censors p53 transcriptional activity. Strikingly, all of the known targets of E4-ORF3, PML 38 , the MRE11/RAD50/NBS1 (NBS1 is also known as NBN) (MRN) DNA damage/repair complex 39 and Tif1a 40 (also known as TRIM24) are subverted by tumour mutations. It is intriguing to speculate that E4-ORF3 physically integrates the inhibitory effects of several cancer pathway mutations, both known and yet to be discovered, which together have emergent functions 4 in silencing p53 activity. Similar to the discovery of p53 with a viral protein 2,3 , E4-ORF3 provides a powerful dynamic probe with which to define critical cellular factors that induce de novo epigenetic silencing of p53 target promoters in somatic cells. This has important implications for understanding how high levels of wild-type p53 might also be inactivated in cancer as well as the dynamic mechanisms that induce aberrant epigenetic silencing of tumour-suppressor gene loci. Finally, our identification of E4-ORF3 changes the fundamental definition of how p53 is inactivated in adenovirus-infected cells, which is a critical mechanistic insight that could now enable the rational development of true p53 tumourselective adenoviral therapies.
METHODS SUMMARY
Cells were grown and infected with established conditions 21, 22 . Protein lysates were analysed by western blotting 21, 22 . Quantitative polymerase chain reaction with reverse transcription (RT-qPCR) was used to quantify p53 targets 21 , and normalized relative to 18S. For luciferase assays, U2OS cells were transfected and infected after 36 h. D-Luciferin (100 mM) was added 4 h post-infection (h.p.i.) and luminescence quantified every hour. Global gene expression was determined using Affymetrix Human Exon 1.0ST arrays and analysed with Partek and Genomatix software. 
METHODS
Cells, growth conditions and viral infections. Primary human cells from multiple donors were obtained from Cambrex/Lonza, which were grown and infected as described previously 21, 22 . Multiplicities of infection (m.o.i.) were determined experimentally. U2OS, H1299-D1, MDA-MB-231, HCT-116, C33A and A549 cells were infected at a m.o.i. of 30, and SAECs, HMEC and HBEC at a m.o.i. of 10. U2OS cells with an IPTG-inducible ARF 41 were a kind gift from G. Peter's laboratory. H1299-D1 is a stable cell line that expresses a p53 cDNA construct under the control of a ponasterone-inducible promoter. To induce p53 expression, cells were treated 5 h before infection with 5 mM ponasterone A (Invitrogen), which was re-added at the time of infection.
Viruses and viral replication assays. Viral replication and titres were quantified by secondary infection of 293/E4/pIX cells using an ELISA assay with a rabbit anti-adenovirus type 5 antibody (Abcam) at 1:1,000, as described previously 21, 22, 42 . Mock infection was performed with the E1-deleted non-replicating adenovirus dl312 (ref. 43 ). Wild-type virus is WtD 18 , DE1B-55k (D55k) is dl1520/ONYX-015 (refs 13, 18) . The DE1B-55k/DE4-ORF3 (D55k/DORF3) virus, dl3112, has an identical genome backbone to dl1520/ONYX-015 but has a single base pair deletion (nucleotide 7143r) that ablates E4-ORF3 expression 44 .
DE4 is dl366 which has a deletion that ablates the E4 genes 45 . DE1B-55k/DE4-ORF6 (D55k/DORF6) is dl367 which has mutations that ablate both E1B-55k and E4-ORF6 (ref 46) . DORF3 is E4inORF3 (ref. 47 ). DE1B-55k/DE1A-13s (D55k/D13s) has an E1B-55k gene deletion and mutation that ablates the 13s splice form of E1A 48 . DE1B-55k/E1ADp300 (D55k/E1ADp300) has an E1B-55k deletion and E1A point mutation that abrogates E1A-p300 binding 21, 48 . Ad-CMV E1-deleted replication-incompetent adenovirus vectors (Ad-CMV-Dest, Invitrogen) were constructed to express either E4-ORF3 (Ad-ORF3) or GFP (Ad-GFP).
Plasmids, drugs and DNA damage. pDONR221 plasmid for SUV39H1 was purchased from the Harvard Institute of Proteomics (Plasmid ID: HsCD00044660) and cloned into a CMV expression vector in frame with an N-terminal myc tag. Doxorubicin (dox, Sigma) at 0.5 mg ml 21 for 12 h was used as a positive control for p53 activation. 5-fluorouracil (Sigma) was used at 50 mg ml 21 , TSA (Sigma) at 5 mM and nutlin-3 (Calbiochem) at 10 mM. c irradiation was performed via exposure to a cobalt-60 source.
Protein lysates and western blot analysis. Protein lysates were harvested, normalized and analysed as described previously 21, 22 . Primary antibodies were from Santa Cruz Biotechnology (p53 DO-1 and FL393, GFP, MDM2 N20), Cell Signaling Technology (phospho-p53 serine (Ser) 6, 9, 15 (16G8), 20, 33, 46, 315, 392 and threonine (Thr) 81), Upstate (p21), Calbiochem (p53 PAb1620 and 240, MDM2 2A10), Abcam (actin and histone H3), Active Motif (H3K9), Ascenion (E4-ORF3 (6A11)), ARF 21 , and E1B-55k (2A6). Actin expression was used as a loading control. Primary antibodies were detected with secondary antibodies labelled with either IRDye800 (Rockland), Alexa Fluor 680 (Molecular Probes) or horseradish peroxidase-conjugated secondary antibodies. Fluorescent antibodies were visualized using a LI-COR-Odyssey scanner and horseradish peroxidase antibodies with ECL chemiluminescence followed by autoradiography.
RT-qPCR analysis. RT-qPCR quantification of p53 transcriptional targets was performed using an ABI Prism 7900 system, as described previously 21 . Total RNA (1 mg) was reverse-transcribed with Applied Biosystems' High Capacity Reverse Transcription. RT-qPCR reactions were set up using Taqman Fast mix (ABI), and run in triplicate. Input cDNA (10 ng) was used for 18S analysis, and 50 ng of input cDNA was used for all other targets. All samples were normalized to 18S expression.
Immunofluorescence. Cells were fixed in 4% paraformaldehyde and stained as described previously 21, 22 . Primary antibodies were from Santa Cruz Biotechnology (p53 DO-1 and FL393, SUV39H2 Z-23), Cell Signaling Technology (SETDB1/ ESET, G9a/EHMT2), Diagenode (H3K9me3 mouse), Active Motif (H3K9me3 rabbit), Abcam (SUV39H2, SUV39H1), and E1A (M73), Roche (myc 9E10), and Ascenion (E4-ORF3 (6A11)). Alexa 488-, 555-and 633-conjugated secondary antibodies (Molecular Probes) were used for detection of primary antibodies. Images were acquired with a Zeiss Axioplan2 imaging system ( Supplementary  Figs 2a, 13, 17 and 20) , a Nikon A1 laser confocal system (Figs 3d, e, 4b and Supplementary Figs 21, 25 and 26 ) and a Leica confocal SP2 ( Supplementary  Figs 18, 19 and 27 ). Pictures were edited in Adobe Photoshop. Background was corrected using same grey level values for all channels to remove noise, except for reducing the contrast of SETDB1 staining for the D55k/DORF3 panel in Supplementary Fig. 21 . The raw microscope images acquired with the Nikon A1 laser confocal system were filtered with a 5 kernel median filter. Chromatin immunoprecipitation assays. p53 and H3K9me3 chromatin immunoprecipitations (ChIPs) were performed as described previously 25, 49 . Cells were fixed with 1% formaldehyde for 15 min and stopped with 0.125 M glycine, lysed in Szak's modified RIPA buffer or 1% SDS lysis buffer and sonicated to shear genomic DNA. p53 and H3K9me3 ChIPs were performed using 2 mg of p53 DO-1 monoclonal antibody and 5 ml of anti-H3K9me3 rabbit serum (Active Motif), respectively. A mouse IgG isotype control and non-immune rabbit serum were used as controls for specificity. Immuno-complexes were isolated using Protein G (mouse antibodies) or Protein A beads (rabbit antibodies). Crosslinking was reversed by incubating at 65 uC overnight. DNA was purified and analysed using either semiquantitative PCR or RT-qPCR using conditions and primers described previously 25, 50, 51 . For RT-qPCR, samples were analysed in duplicate using a Sybr GreenER mix (Invitrogen) and quantified on a MyiQ RT-qPCR machine (Bio-Rad). A tenfold dilution series of input DNA was used to determine the efficiency of the PCR for each primer set. ChIP DNA samples were normalized relative to their respective input DNAs. Affymetrix expression arrays and data analysis. Human primary quiescent SAECs were infected and harvested at 36 h.p.i. All samples were done in duplicate, and corresponding lysates were western-blotted. Total RNA was isolated and purified using TRIzol with the PureLink RNA Mini kit (Invitrogen), and treated with DNase I (Ambion). Total RNA (100 ng), spiked with Poly-A controls, was used to synthesize cDNA, according to recommended protocols using the Ambion WT Expression kit. Fragmentation and labelling of cDNA was performed as per the Affymetrix GeneChip WT Terminal Labeling standard protocol. Samples were hybridized to Affymetrix Human Exon 1.0ST arrays, washed, stained and scanned with the Affymetrix GCS 3000 7G and GeneChip Operating Software v1.3 to produce .CEL intensity files. Quality control analysis of all chips was performed with the Affymetrix expression console. All array data were analysed using tools in the Partek Genomic Suite of software (Partek) 52 . Exon-level data were imported and filtered to include only those probes that are in the 'Core Meta-probeset', which represents 17,800 RefSeq genes and full-length GenBank mRNAs. A pre-background adjustment was performed for GC content followed by robust multi-array analysis (RMA) background correction, quantile normalization and mean probeset summarization 53, 54 (Supplementary Fig. 29 ). Sources of variation due to random experimental factors, such as scan date and experiment were batch-removed using analysis of variance (ANOVA). The fold-change and p-values for differentially expressed genes between D55k/DORF3 versus mock, D55k versus mock, D55k/DORF3 versus D55k and nutlin versus mock were determined using linear contrasts in a oneway ANOVA model using method of moments 52 . The ANOVA model used was:
where Y ij represents the jth observation on the ith virus/treatment, m is the common effect for the whole experiment and e ij represents the random error present in the jth observation on the ith virus/treatment. The errors e ij are assumed to be normally and independently distributed with mean 0 and standard deviation s for all measurements. A step-up false discovery rate (FDR) of 0.05 was applied to p-values calculated by ANOVA as the cut-off for significant differentially expressed genes.
Differentially expressed genes were analysed using the Genomatix Pathway System (GePS) and GeneRanker programs, which uses information extracted from public and proprietary databases. Over-representation of different biological terms (Gene Ontology categories, signal transduction pathways) within the input gene list are calculated and listed together with their respective p-value 55 . Signal Transduction Pathway Associations are obtained by Genomatix with a proprietary literature data mining algorithm based on all available Pubmed abstracts. Promoter analysis. Genomatix Gene2Promoter was used to retrieve the optimized promoters of the 265 differentially upregulated transcripts in D55k/ DORF3versus D55k-infected SAECs and filter them for p53 transcription factor binding sites (TFBS) using MatInspector 56 . MatInspector searches transcription factor matrix matches based on position weight matrices 57 , which has been used successfully to detect functional p53 transcription factor elements 58 . Six different matrices for p53 were used as described in Supplementary Table 4 . Default
